Single-gene rejuvenation target promises safer cell age reversal

Table of Contents

Shift Bioscience identifies potent, pluripotency-free alternative to OSKM, with implications for the future of cell rejuvenation therapeutics.

After decades of research into the molecular mechanisms of aging, the allure of reversing cellular time has become both a scientific ambition and a commercial imperative. Yet despite promising results with partial reprogramming techniques such as the Yamanaka factors (OSKM), safety concerns – particularly those relating to unwanted pluripotency and tumorigenesis – have limited their therapeutic applicability.

A cleaner route to cellular youth

In an announcement today, Cambridge-based biotech Shift Bioscience has introduced a potential alternative: SB000, a novel single-gene target that appears to reverse markers of cellular aging across multiple cell types without triggering the dedifferentiation cascade associated with pluripotency. The research, detailed in a not-yet-peer-reviewed preprint, presents a striking result: comparable efficacy to OSKM in both methylomic and transcriptomic rejuvenation, but without the pluripotency-associated risks that have dogged OSKM’s translational prospects.

Longevity.Technology: The search for safe, effective cellular rejuvenation has long been hampered by the paradox of OSKM – powerful in reversing biological age, but too risky for therapeutic use due to its activation of pluripotency pathways. Shift Bioscience’s identification of SB000 as a single-gene alternative represents a potential inflection point for the field. SB000 matches or exceeds OSKM’s rejuvenative effect across transcriptomic and DNA methylation clocks, yet crucially maintains cell identity and avoids the tumorigenic pitfalls of reprogramming. That this was achieved with a single gene – rather than a complex cocktail – marks a major step forward in the practical translatability of cellular rejuvenation therapies.

The implications go beyond scientific elegance; a single-gene intervention dramatically simplifies vector engineering, dose optimisation, and regulatory pathways. Moreover, the observed functional rejuvenation – including enhanced collagen production and preserved fibroblast behavior – points toward tangible therapeutic value in tissues most affected by age-related decline. The broad applicability across both mesoderm- and ectoderm-derived cell types suggests SB000 could underpin a versatile platform for treating a wide range of degenerative conditions. Combined with the high-resolution, AI-driven discovery engine behind it, SB000 strengthens the case for Shift Bioscience as a commercially serious player in the emerging rejuvenation therapeutics market.

A new data-first discovery platform

At the heart of Shift’s discovery is a machine learning-guided screening platform that sidesteps the limitations of traditional methylation assays by focusing on single-cell transcriptomic clocks. The company’s AC3 clock, trained on a wide donor pool aged from one to 87, enabled a high-throughput screening of 1,500 candidate genes. SB000 emerged from this screen with rejuvenative effects that not only rivalled OSKM, but also exhibited remarkable consistency across donors and cell types [1].

Following its identification, SB000 was tested in both dermal and lung fibroblasts as well as in keratinocytes – capturing two of the three embryonic germ layers. Treated cells showed reductions in epigenetic age as measured by several clocks including GrimAge2 and DunedinPACE, with PCHorvath2013 showing a drop of more than 13 years in keratinocytes. Notably, this reversal occurred without loss of cellular identity and without activation of markers associated with pluripotency.

The magnitude and consistency of effect are important – but so too is functional behavior. SB000-treated fibroblasts retained normal morphology, did not form colonies and maintained or even enhanced production of collagen I, a marker of youthful fibroblast function. In contrast, cells exposed to OSKM or even partial OSK combinations were shown to diverge toward pluripotency pathways and, in some cases, lost key features of their original identity.

Applications and next steps

Shift Bioscience’s approach – one that prioritizes age reversal without dedifferentiation – opens a clearer route to therapeutic development. Rejuvenated cells that behave like their younger counterparts but retain their function and identity are essential for developing treatments for age-driven diseases; pluripotent or semi-reprogrammed cells, by contrast, introduce unacceptable risk in most clinical contexts.

CEO Dr Daniel Ives is keenly aware of the broader implications. “The discovery of SB000 marks a major milestone, both for Shift and for the cell rejuvenation field more broadly, and demonstrates the power of our unique, dataset-driven approach to target identification,” he said in the announcement. “Offering comparable efficacy to the Yamanaka Factors without the safety concerns associated with pluripotency, SB000 is well positioned as a target for next-generation, safer cellular rejuvenation therapeutics, helping us bring about a future where we have substantial control over the aging process and age-related diseases.”

Writing on X this morning, Ives expanded on the tension between long-term vision and near-term deliverables: “The dream of waking up in the near future and being substantially younger at a cellular level is something I have the rare privilege to pursue each day. However, keeping this dream alive is contingent on the following (1) making timely and meaningful technical progress towards the end-goal (2) finding a spectacular short- and long-term commercial story, given the significant upfront time and capital investment required for drug development (3) nourishing the excitement and clarity of this mission, lest we settle for less on what will be a challenging journey.”

For that story to unfold, the next chapters will be crucial. Shift plans to broaden its testing across additional cell types before advancing to in vivo proof-of-concept studies in mouse models – a necessary step, given that SB000 has yet to demonstrate in vivo the systemic effects observed with OSKM, which extended lifespan in animal models. While SB000’s profile is compelling at the cellular level, its therapeutic promise will ultimately depend on successful translation to whole-organism contexts.

Shift will also need to demonstrate that its approach can achieve the gold standard of rejuvenation therapeutics: long-term safety, durability of effect and disease-relevant outcomes in whole organisms – what amounts to the field’s triple threat. In a field where many promising interventions falter between cell culture and the clinic, these milestones will be closely watched.

A shifting landscape

While the findings are promising, it is worth noting that the work remains a preprint and has not yet undergone peer review. That said, the data-rich nature of the paper – complete with independent validation across multiple assays and cell types – lends confidence in its integrity, even as formal validation awaits.

The rejuvenation field is, as ever, characterized by bold claims and cautious optimism. What sets Shift’s announcement apart is not just the potency of the target, but the groundedness of its approach – using data to narrow risk, refining technology to increase safety, and designing with translatability in mind.

Aging may be universal, but the tools we use to address it are becoming more precise. As research such as this moves closer to clinical testing, the emphasis must remain on rigorous validation, scalable delivery and, perhaps most importantly, the avoidance of shortcuts. The potential of SB000 lies not only in what it may achieve, but in the careful, calculated steps Shift seems willing to take to get there.

Daniel Ives will be speaking at tomorrow’s Founders Longevity Forum London event. A live audience Q&A will follow his presentation on on epigenetic and partial cellular reprogramming to restore cellular function.